FEATURES OF CHANGES IN PLATELET FUNCTIONAL ACTIVITY IN PATIENTS WITH CORONARY ARTERY DISEASE AND HYPERTENSION DEPENDING ON SENSITIVITY TO ANTIPLATELET DRUGS

Authors:

Abstract:

Hypertension is an urgent problem of cardiology, due to its prevalence and adverse complications. The purpose of the study was to optimize the diagnosis and treatment of patients with coronary artery disease and hypertension based on the researching of functional activity of platelets and the effectiveness of antiplatelet therapy. A total of 147 patients were included, the control group consisted of 30 people. It was determined that 54% of patients treated with acetylsalicylic acid had impaired sensitivity to treatment and 27% – to thienopyridine drugs. The most noticeable changes were observed in the degree of induced platelet aggregation with arachidonic acid and collagen among patients receiving acetylsalicylic acid, and thienopyridines as for adenosine diphosphate – and adrenaline-induced platelet aggregation. Given the heterogeneity of indices in groups of patients with hypertension and various forms of coronary artery disease, the study of vascular-platelet hemostasis in the whole blood by express method makes it possible to more accurately determine the degree of sensitivity to antiplatelet therapy.

Keywords:

hypertension coronary artery disease vascular-platelet hemostasis sensitivity to antiplatelet therapy

References:

1. Zhemaniuk SP, Syvolap VV. Osoblyvosti adrenalin-indukovanoi agregacii trombocytiv u khvorykh na esentsialnu gipertenziu v gostromu periodi pivkulnogo ishemichnogo insultu za danymy turbidymetrychnoi agregatometrii. Patologia; 2017; 1: 68–74 [in Ukrainian]
2. Medvedev IN, Skoriatina IA. Agregatsionnye svoistva formennykh elementov krovi i sosudistyi control nad nimi u bolnykh arterialnoy gipertoniey s dislipidemiey. Ros. cardiol. zhurnal; 2015; 4: 18–22 [in Russian]
3. Netiazhenko VZ, Drofa LB, Mishanich GI. Vyvchennia actyvnosti trombocytarnogo gemostazu u khvorykh z riznymy formamy ichemichnoi khvoroby sertsia, poiednanoi iz tsukrovym diabetom 2 typu. Medycyna trancpotru Ukrainy; 2012; 2: 15–19 [in Ukrainian]
4. Ovrakh TG. Trombocytarnyi gemostaz ta porushennia vuglevodnogo obminu u khvorych na ishemichnu khvorobu sertsia v poiednanni z tsukrovym diabetom 2-go typu pry podviyniy antytrombocytarniy terapii. Krovoobig ta gemostaz; 2015; 1/2: 133 [in Ukrainian]
5. Pokaznyky zdorovia naselennya ta vykorystannya resursiv okhorony zdorovya v Ukraini za 2017 r. / DZ «Nsentr medychnoi statystyky» [Internet]. Kyiv, 2017. Dostupno na: http: //medstat.gov.ua/ukr/statdan.html [in Ukrainian]
6. Fedotova LA. Funkcionalnaya aktivnost gemostaza i fibrinoliza u patsientiv s ishemicheskoy bolezniu serdtsa v dinamike kardiocytoprotektornoy terpii. Krovoobig ta gemostaz; 2014; 1/2: 110–114 [in Russian]
7. Fushtey IM, Podsevakhina SL, Palamarchuk AI. Medikamentoznaya korrekciya endotelialnoy disfunkcii u bolnykh s arterialnoy gipertenziey v sochetanii s vospalitelnymi zabolevaniyami sustavov. Simeyna medicina; 2016; 1 (63):75–78 [in Ukrainian]
8. A global brief on hypertension. Silent killer, global public health crisis [Internet]. World health Day 2013. Geneva : World Health Organization; 2013. Available from: http ://www.ish-world.com.
9. Aradi D, Storey RF, Komocsi A. et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal; 2014; 35: 209–215.
10. Gengo F, Westphal ES, Rainka MM. Platelet response to increased aspirin dose in patients with persistent platelet aggregation while treated with aspirin 81 mg. The Journal of Clinical Pharmacology; 2016; 56 (4): 414–421. Doi: 10.1002/jcph.608.
11. Kotseva K, Wood D, De Bacquer D. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology; 2016; 23: 636–648.
12. Mayer K, Bernlochner I, Braun S. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISARASPI Registry. Journal of the American College of Cardiology; 2014; 64: 863–871.
13. Niaz S, Latif J, Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pakistan J. Med. Sci. 2019; 35 (3): 641–646. Doi: 10.12669/pjms.35.3.274
14. Somuncu MU, Demir AR, Karakurt ST. Long Term Cardiovascular Outcome Based on Aspirin and Clopidogrel Responsiveness Status in Young ST-Elevated Myocardial Infarction Patients. Arquivos Brasileiros de Cardiologia; 2019; 112 (2): 138–146. Doi: 10.5935/abc.20180251
15. Vlachopoulos C, Ioakeimidis N, Stefanadis C. Biomarkers, erectile dysfunction, and cardiovascular risk prediction: the latest of an evolving concept. Asian Journal of Andrology. 2015; 17: 17–20. Doi: 10.4103/1008-682X.143250.

Publication:

«World of Medicine and Biology» Vol. 16 No. 74 (2020) , с. 111-115
УДК 616.127-005.4:616.151.5-085.273.53:57.017.4

DOI:

https://doi.org/10.26724/2079-8334-2020-4-74-111-115